Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415783 | 0.90 | MTNR1A (0.42) | SRD5A1CYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL19224617 | 0.90 | MTNR1A (0.42) | SRD5A1CYP11B2CYP11B1CYP19A1CYP17A1 | |
| SCHEMBL2398711 | 0.84 | ADRA2A (0.41) | CYP1A2MTNR1ACHRM1CHRM2HTR1A | |
| SCHEMBL19481568 | 0.79 | HTR2A (0.41) | CYP1A2MTNR1ACHRM1DRD2KCNH2 | |
| SCHEMBL28618030 | 0.79 | GRIN2D (0.40) | CYP11B2CYP11B1MTNR1ACHRM1DRD2 | |
| SCHEMBL25921033 | 0.79 | MTNR1A (0.40) | CYP1A2MTNR1ACHRM1DRD2KCNH2 | |
| SCHEMBL13019291 | 0.78 | MTNR1A (0.38) | CYP11B2CYP11B1MTNR1ACHRM1DRD2 | |
| SCHEMBL28708105 | 0.78 | CYP1A2 (0.48) | CYP11B2CYP11B1CYP1A2MTNR1ACHRM1 | |
| SCHEMBL9514825 | 0.78 | CRBN (0.38) | CYP11B2CYP11B1CYP19A1CYP17A1CYP1A2 | |
| SCHEMBL28709051 | 0.78 | MTNR1A (0.38) | CYP11B2CYP11B1CYP19A1CYP17A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109575050-B | Gossypol-7-N heteroisatin Schiff base compounds with anti-tumor activity and synthesis method thereof | 陕西盘龙药业集团股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-109438323-B | Gossypol-7-N heteroisatin Schiff base compounds with anti-tumor activity and synthesis method thereof | 陕西盘龙药业集团股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-2393806-B1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARM INC (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2011151436-A2 | NOVEL COMPOUNDS, METHOD FOR USE THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | EUROSCREEN S.A. (BE) | 2011-12-08 | — | — | WO | disclosed |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | SRD5A1 135/4885CYP11B2 13/4885CYP11B1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.